GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes

Contact sales for details.

Only 34% of GLP-1 patients on DPP-4 inhibitors, a class of oral diabetic medications also known as gliptins, were still taking DPP-4 inhibitors 52 weeks after starting GLP-1 therapy according to Earnest pharmacy claims data. The decline in DPP-4 usages is likely due to the fact that most are not effective in combination with GLP’s. This is just one of the many lasting impacts of the diabetes and weight loss GLP-1 drugs like Wegovy, Ozempic, and Mounjaro. 

In contrast, SGLT2s are effective in combination with GLP1s. In fact, there is a slight increase in the number of patients taking SGLT2s after they start on GLP1s. 

Insulin, which remains top of mind for possible GLP-1 impact, saw only a slight reduction in use post GLP-1 adoption.  Only 84% as many patients are active on insulins at month 12 as compared to month 0 of GLP1 therapy.

See GLP-1 Series Part 3 for more on insulin disruption by drug.

Data Disclaimer:

Results reflect data as of December 7th, 2023 when they were prepared. Current results may have changed due to panel and methodology updates.